APLT (Applied Therapeutics) Debt-to-Equity : 0.34 (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Applied Therapeutics Debt-to-Equity?

Applied Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.26 Mil. Applied Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.71 Mil. Applied Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $5.89 Mil. Applied Therapeutics's debt to equity for the quarter that ended in Sep. 2024 was 0.33.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Applied Therapeutics's Debt-to-Equity or its related term are showing as below:

APLT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.44 Med: 0.03 Max: 0.37
Current: 0.34

During the past 7 years, the highest Debt-to-Equity Ratio of Applied Therapeutics was 0.37. The lowest was -0.44. And the median was 0.03.

APLT's Debt-to-Equity is ranked worse than
67.09% of 1015 companies
in the Biotechnology industry
Industry Median: 0.14 vs APLT: 0.34

Applied Therapeutics Debt-to-Equity Historical Data

The historical data trend for Applied Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Therapeutics Debt-to-Equity Chart

Applied Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.06

0.03

0.37

-0.05

Applied Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															-0.12	-0.05	0.01	-	0.34

Competitive Comparison of Applied Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Applied Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Applied Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Applied Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Applied Therapeutics's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Applied Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Applied Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.739	+	0.038)	/	-17.146
	=	-0.05

Applied Therapeutics's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.264	+	1.707)	/	5.892
	=	0.33

Applied Therapeutics (NAS:APLT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Applied Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Applied Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Applied Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Therapeutics Inc (NAS:APLT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

2UV:Germany

Address

545 Fifth Avenue, Suite 1400, New York, NY, USA, 10017

Website

https://www.appliedtherapeutics.com

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Executives

Riccardo Perfetti	officer: Chief Medical Officer	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Leslie D. Funtleyder	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Shoshana Shendelman	director, 10 percent owner, officer: President and CEO	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Alexandria Real Estate Equities, Inc.	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101
Adam Hansard	officer: Chief Commercial Officer	C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE, SUITE 1400, NEW YORK NY 10017
Stacy J. Kanter	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Catherine Thorpe	officer: Chief Accounting Officer	545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Chids Mahadevan	officer: Chief Accounting Officer	C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Steven A. Ortega	officer: Principal Accounting Officer	C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Charles Silberstein	officer: Chief Financial Officer	C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Joel S Marcus	director	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Alexandria Equities No. 7, Llc	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101
Jay S Skyler	director	DANCE BIOPHARM INC., 150 NORTH HILL DRIVE, SUITE 24, BRISBANE CA 94005
Alexandria Venture Investments, Llc	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101
Teena Lerner	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173